New Technology– category –
-
Moderna’s RSV Vaccine mRESVIA® Receives FDA Approval as mRNA Therapeutics Advance in Non-Vaccine Applications
Facebook (Vaxcyte, Vivaldi Biosciences) USA Overview Moderna's RSV vaccine mRESVIA® gained FDA approval following Breakthrough Therapy Designation, reaffirming the power of mRNA technology in infectious disease prevention. Concurrently, ... -
The Pharma AI Data Problem: Complex Clinical Trial Data Impedes AI Model Development and Deployment
ACI Infotech USA Overview Despite significant investments in AI within the pharmaceutical sector, the structural complexity and inconsistency of clinical trial data present a major 'clinical trial data problem,' hindering the effective d... -
Insitro Appoints Hideo Makimura as Chief Medical Officer to Accelerate Transition from AI Drug Discovery to Clinical-Stage Company
BioSpace USA Overview Insitro, a pioneer in AI drug discovery, announced the appointment of Hideo Makimura as Chief Medical Officer (CMO), signaling a strategic acceleration from an AI-driven discovery firm to a clinical-stage company. M... -
Novartis’ DM1 Therapeutic Delpacibart Etedesiran Fails to Meet Primary Endpoint in Phase III HARBOR Study
Novartis Switzerland Overview Novartis announced that its antibody-oligonucleotide conjugate (AOC) delpacibart etedesiran (del-desiran) for myotonic dystrophy type 1 (DM1) did not achieve a statistically significant improvement in the pr... -
Tangram Therapeutics Advances TGM-312 to Patient Cohorts in Phase 1/2 RESTORE-MASH Trial for MASH Treatment
BioSpace USA Overview Tangram Therapeutics announced the progression of TGM-312, a novel GalNAc-siRNA therapeutic for MASH (Metabolic Dysfunction-Associated Steatohepatitis), to patient cohorts in its Phase 1/2 RESTORE-MASH trial. TGM-31... -
Silence Therapeutics’ PV Drug Divesiran Achieves 88% Response Rate in Phase 2, Advances to Phase 3
Investing.com UK Overview Silence Therapeutics' GalNAc-siRNA therapeutic, divesiran, for polycythemia vera (PV) met its primary endpoint in the Phase 2 SANRECO study, demonstrating an impressive 88% response rate compared to 19% in the p... -
Gan & Lee’s First-in-Class AR PROTAC GLR2037 Receives NMPA Approval to Initiate Clinical Trials for Advanced Prostate Cancer
flcube.com China Overview Gan & Lee Pharmaceuticals announced that China's National Medical Products Administration (NMPA) has approved its first-in-class androgen receptor (AR) PROTAC, GLR2037, for clinical trials. This novel therap... -
First PROTAC Therapy for Breast Cancer Approved, Opening New Avenues for Precision Medicine in Advanced, Metastatic Disease with Specific Mutations
Nature Medicine Journal (Facebook) International Overview A PROTAC therapy for breast cancer has received medical approval, pioneering a new era of precision medicine for patients with advanced or metastatic breast cancer harboring speci... -
FDA Grants Breakthrough Therapy Designation to JBS-003 (18F-FMISO), First PET Tracer to Guide Radiation De-escalation in HPV-Positive Oropharyngeal Cancer
Cancer Network USA Overview The U.S. FDA has granted Breakthrough Therapy Designation to JBS-003 (18F-fluoromisonidazole [FMISO]), the first hypoxic PET tracer intended to identify tumor hypoxia and guide radiation therapy de-escalation ... -
Antibody-Drug Conjugates Prepared with Peptide Asparaginyl Ligase Enhance Uniformity and Antitumor Activity, Promising Pharmaceutical Applications
Molecular Cancer Therapeutics (AACR Journals) USA Overview Novel antibody-drug conjugates (ADCs) prepared using peptide asparaginyl ligase (PAL) demonstrated potent antitumor activity in both in vitro and in vivo models. This innovative ...
